EUVIMEDEUVIMED entdecken
Klinische Studie (Phase III)VergleichsstudieMultizentrische StudieRandomisierte kontrollierte Studie

Patient-Relevant Outcomes From the Phase III MARIPOSA-2 Trial: Amivantamab-Chemotherapy Versus Chemotherapy in EGFR-Mutant Advanced Non-Small-Cell Lung Cancer Following Disease Progression on Osimertinib

Pascale Tomasini, Oscar Juan-Vidal, Raffaele Califano, Chien-Chung Lin, Pauline Hulo, Christophe Dooms, Jian Fang, Ana Blasco, Dariusz Kowalski, Jorge Salinas, Govind Babu, Tho Lye Mun und 20 weitere

Clinical Lung Cancer · 2026

DOI: 10.1016/j.cllc.2025.12.005 ↗

Kurz gefasst

Klinische Studie (Phase III) in der Zeitschrift Clinical Lung Cancer, 2026. Verfasst von Pascale Tomasini und 31 weiteren Autor:innen. Beteiligte Einrichtung: Aix Marseille University Hospital Nord, Multidisciplinary Oncology and Therapeutic Innovations Department, Marseille, France. Electronic address: pas…. Hauptthemen laut MEDLINE: Acrylamides, Aniline Compounds, Antineoplastic Combined Chemotherapy Protocols, Carcinoma, Non-Small-Cell Lung. Die Arbeit nennt 27 Literaturangaben. Gefördert von: Janssen Research and Development, Johnson and Johnson.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

OBJECTIVE: The MARIPOSA-2 study demonstrated improved progression-free survival with amivantamab and chemotherapy compared with chemotherapy alone in patients with EGFR-mutated locally advanced or metastatic non-small-cell lung cancer (NSCLC) with disease progression on or after treatment with osimertinib. This publication describes the results of patient-reported outcomes (PROs) measures and time to symptomatic progression (TTSP) for 2 treatment arms. METHODS: PRO instruments included the European Organization for Research and Treatment of Cancer Quality of Life (QoL) Questionnaire Core 30 (EORTC QLQ-C30), Patient-Reported Outcomes Measurement Information System Physical Function Short Form 8c, and the NSCLC Symptom Assessment Questionnaire. Changes from baseline were analyzed using mixed-effects models for repeated measures. Treatment comparisons were based on least-squares means. The hazard ratio for TTSP was estimated using a stratified Cox regression model with P value derived from a stratified log-rank test. RESULTS: Patients received amivantamab-chemotherapy (n = 131) or chemotherapy alone (n = 263). PRO scores were stable over time with little or no group differences in least-squares mean change from baseline. At 6 months postbaseline, 55.1% of patients in the amivantamab-chemotherapy arm reported improved or stable EORTC QLQ-C30 global health status/QoL scores compared with 29.1% in the chemotherapy arm. TTSP was prolonged for the amivantamab-chemotherapy treatment group versus chemotherapy alone (hazard ratio [HR] [95% CI], 0.73 [0.55-0.96]; nominal P = .0259). CONCLUSION: PRO results indicate that the clinical benefits of adding amivantamab to chemotherapy were achieved without compromising health-related QoL. Amivantamab-chemotherapy prolonged TTSP versus chemotherapy alone.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AcrylamidesAniline CompoundsAntineoplastic Combined Chemotherapy ProtocolsCarcinoma, Non-Small-Cell LungLung NeoplasmsAgedFemaleHumansMaleMiddle AgedDisease ProgressionErbB ReceptorsIndolesMutationPatient Reported Outcome MeasuresPyrimidinesQuality of Life

Stichwörter der Autor:innen

Health-related quality of lifePatient-centered outcomesPatient-reported outcomesPhysical functionTime to symptomatic progression

Substanzen

AcrylamidesAniline CompoundsEGFR protein, humanErbB ReceptorsIndolesosimertinibPyrimidines

Autor:innen und Institutionen

  • Aix Marseille University Hospital Nord, Multidisciplinary Oncology and Therapeutic Innovations Department, Marseille, France. Electronic address: pascale.tomasini@ap-hm.fr.
  • Department of Medical Oncology, University Hospital La Fe, Valencia, Spain.
  • The Christie NHS Foundation Trust and Division of Cancer Sciences, The University of Manchester, Manchester, United Kingdom.
  • National Cheng Kung University Hospital, Tainan, Taiwan.
  • Thoracic Oncology Unit, Nantes University Hospital, Nantes, France.
  • UZ Leuven, Leuven, Belgium.

Förderung

  • Janssen Research and Development
  • Johnson and Johnson

Zitieren

APA

Tomasini, P., Juan-Vidal, O., Califano, R., Lin, C. C., Hulo, P., Dooms, C., Fang, J., Blasco, A., Kowalski, D., Salinas, J., Babu, G., Mun, T. L., Bearz, A., Surmont, V., Baldotto, C., Sharma, R., Arrieta, O., Stencel, K., Card, C., …, & Felip, E. (2026). Patient-Relevant Outcomes From the Phase III MARIPOSA-2 Trial: Amivantamab-Chemotherapy Versus Chemotherapy in EGFR-Mutant Advanced Non-Small-Cell Lung Cancer Following Disease Progression on Osimertinib. Clinical Lung Cancer. https://doi.org/10.1016/j.cllc.2025.12.005

Vancouver

Tomasini P, Juan-Vidal O, Califano R, Lin CC, Hulo P, Dooms C, et al. Patient-Relevant Outcomes From the Phase III MARIPOSA-2 Trial: Amivantamab-Chemotherapy Versus Chemotherapy in EGFR-Mutant Advanced Non-Small-Cell Lung Cancer Following Disease Progression on Osimertinib. Clinical Lung Cancer. 2026. doi:10.1016/j.cllc.2025.12.005

BibTeX
@article{Tomasini2026,
  author = {Tomasini, Pascale and Juan-Vidal, Oscar and Califano, Raffaele and Lin, Chien-Chung and Hulo, Pauline and Dooms, Christophe and Fang, Jian and Blasco, Ana and Kowalski, Dariusz and Salinas, Jorge and Babu, Govind and Mun, Tho Lye and Bearz, Alessandra and Surmont, Veerle and Baldotto, Clarissa and Sharma, Richu and Arrieta, Oscar and Stencel, Katarzyna and Card, Cynthia and Zer, Alona and Massarelli, Erminia and Fang, Bruno and Mashru, Sandeep and Schuchard, Julia and Sermon, Jan and Diels, Joris and Chu, Pei-Ling and Withelder, Monica and Bauml, Joshua M and Shah, Sujay and Baig, Mahadi and Felip, Enriqueta},
  title = {Patient-Relevant Outcomes From the Phase III MARIPOSA-2 Trial: Amivantamab-Chemotherapy Versus Chemotherapy in EGFR-Mutant Advanced Non-Small-Cell Lung Cancer Following Disease Progression on Osimertinib},
  journal = {Clinical Lung Cancer},
  year = {2026},
  doi = {10.1016/j.cllc.2025.12.005}
}
Kostenlos starten →